StreetAlpha.app
Home › Stocks › TNGX

Tango Therapeutics, Inc. (TNGX)

Healthcare
$21.73
▼ −4.32%
LAST CLOSE · NOV 20

Tango Therapeutics develops targeted cancer medicines that aim to kill tumor cells with specific genetic alterations. It last closed at $21.73 on Nov 20, down 4.32% on the day. The next earnings report for TNGX is expected around Thu, Mar 4, 2027. For the quarter ended Sep 2026, TNGX reported EPS of -$0.39 on revenue of $0, with revenue down 100.0% from a year ago. Over its last 8 reports the stock moved an average of 11.1% the session after earnings. Over the last 12 months TNGX insiders bought $0 of stock on the open market and sold $8.2M, according to SEC Form 4 filings.

AI Auto Pilots
Is TNGX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold TNGX.

Key Stats

Last 12 months
Results
Revenue
$0
−100.0% vs a year ago
Net income
−$208.0M
EPS (diluted)
−$1.38
Free cash flow
−$150.4M
Valuation
Market cap
$3.7B
169.5M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$86.8M
At Sep 30
Shareholder equity
$980.2M
Shares outstanding
169.5M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $37.0M$37.0MFY2021FY2022: $24.9M$24.9MFY2022FY2023: $36.5M$36.5MFY2023FY2024: $42.1M$42.1MFY2024FY2025: $62.4M$62.4MFY2025

From TNGX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Mar 4
Estimated date · Time not announced
Reported EPS
-$0.39
Quarter ended Sep 2026
Year ago EPS
$0.13
−400.0% on a GAAP basis
Revenue
$0
−100.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.34Dec '24Mar 2025: -$0.36Mar '25Jun 2025: -$0.35Jun '25Sep 2025: $0.13Sep '25Dec 2025: -$0.30Dec '25Mar 2026: -$0.32Mar '26Jun 2026: -$0.37Jun '26Sep 2026: -$0.39Sep '26Latest -$0.39
Revenue by quarter
Dec 2024: $4.1MDec '24Mar 2025: $5.4MMar '25Jun 2025: $3.2MJun '25Sep 2025: $53.8MSep '25Dec 2025: $0Dec '25Mar 2026: $0Mar '26Jun 2026: $0Jun '26Sep 2026: $0Sep '26Latest $0
How TNGX moved after its last 8 reports
Average move the session after a report ±11.1%
Nov 9, 2026Time not announced+5.8%
Aug 11, 2026Time not announced−4.8%
May 13, 2026After the close−2.5%
Mar 5, 2026Time not announced+36.3%
Jan 8, 2026Time not announced−6.2%
Oct 23, 2025Time not announced−13.1%
Aug 5, 2025Time not announced+4.9%
May 12, 2025Time not announced+14.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on TNGXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on TNGX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on TNGX

Technical Analysis

TNGX · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend

The stock is 6% below its 20 day and 8% below its 50 day average. It is 7% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 44). The nearest support is the swing low (Oct 30) at $21.71, and the nearest resistance the Pivot at $22.14.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 8.6%/day
Key levels
$34.3952 week high+58.3%
$24.97100 day average+14.9%
$23.49Swing high (Jun 1)+8.1%
$23.4550 day average+7.9%
$23.16200 day average+6.6%
$22.9420 day average+5.6%
$22.64Pivot R1+4.2%
$22.14Pivot+1.9%
$21.73Last close
$21.71Swing low (Oct 30)−0.1%
$21.22Pivot S1−2.3%
$8.3052 week low−61.8%
Indicators
RSI (14)44.43Middle of its rangeNeutral
MACD-0.21Below its signal lineBearish
Stochastic24.2Middle of its rangeNeutral
ADX (14)11.7No clear trend
Williams %R-82.5Oversold below −80, overbought above −20Oversold
CCI (20)-69.3Oversold below −100, overbought above 100Neutral
Rate of change+1.1%Change over 10 sessionsBullish
ATR (14)$1.86Typical daily range, 8.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for TNGX

What happened before

See how TNGX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow TNGX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How TNGX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for TNGXHow many large options trades hit TNGX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

TNGX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲156 buying vs 101 selling
  • ●Held by funds +0.1 pts
  • ▲Funds holding +10
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding257247+4.0%
In funds' top 1019190.0%
Held by funds126.8%126.7%+0.1 pts
New / increased46 / 11073 / 102−10.9%
Reduced / sold out66 / 3555 / 23+29.5%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TNGX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

TNGX Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$8.2M19 sales · 5 insiders
91% of the selling was under pre-arranged trading plans.
2026-02 sold $1.4M2026-03 sold $545K2026-04 sold $1.5M2026-05 sold $573K2026-06 sold $618K2026-07 sold $799K2026-08 sold $736K2026-09 sold $803K2026-10 sold $661K2026-11 sold $475KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 17John B KetchumDirectorSale plan3,333$24.08$80K
Nov 11Adam CrystalPresident, R&DSale plan5,000$25.00$125K
Nov 2Jessica NewcombPrincipal Accounting OfficerSale plan7,031$22.42$158K
Nov 2Adam CrystalPresident, R&DSale plan5,000$22.42$112K
Oct 1Adam CrystalPresident, R&DSale plan27,000$24.47$661K
Sep 22Jessica NewcombPrincipal Accounting OfficerSale plan8,200$24.22$199K
Every insider buy and sale for TNGX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See TNGX insider trades →

From SEC Form 4 filings by TNGX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TNGX is in one of them and how their past TNGX trades turned out.

TNGX in the AI portfolios
Loading…

TNGX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TNGX in an article yet. Here's the latest on the wider market.

TNGX in the news

About Tango Therapeutics

Tango Therapeutics is a biopharmaceutical company based in Boston, Massachusetts, that develops targeted cancer medicines. Its lead candidates are small molecule drugs designed to kill cancer cells that carry specific genetic changes while largely sparing normal cells. Its main programs target the PRMT5 protein in cancers with a specific gene deletion, including pancreatic and lung cancers and glioblastoma, a type of brain cancer. The company aims to treat patients whose tumors share these genetic features.

Headquarters
Boston, MA
Founded
2017